



## **Prothena to Report Fourth Quarter and Full Year 2018 Financial Results and Host Webcast Conference Call on February 14**

February 4, 2019

DUBLIN, Ireland, Feb. 04, 2019 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a clinical-stage neuroscience company, announced today that it will report its fourth quarter and full year 2018 financial results on Thursday, February 14<sup>th</sup>, after the close of the U.S. financial markets. The announcement will be followed by a live audio conference call at 4:30 PM ET.

The conference call will be made available on the Company's website at [www.prothena.com](http://www.prothena.com) under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for at least 90 days.

To access the call via dial-in, please dial (877) 887-5215 (U.S. and Canada toll free) or (315) 625-3069 (international) five minutes prior to the start time and refer to conference ID number 3791173. A replay of the call will be available until February 28, 2019 via dial-in at (855) 859-2056 (U.S. toll free) or (404) 537-3406 (international), Conference ID Number 3791173.

### **About Prothena**

Prothena Corporation plc is a clinical-stage neuroscience company focused on the discovery and development of novel therapies with the potential to fundamentally change the course of progressive, life-threatening diseases. Fueled by its deep scientific understanding built over decades of neuroscience research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets including Parkinson's disease and other related synucleinopathies (prasinezumab - PRX002/RG7935) and ATTR amyloidosis (PRX004), as well as tau, A $\beta$  (Amyloid beta) and TDP-43 where its scientific understanding of disease pathology can be leveraged. For more information, please visit the Company's website at [www.prothena.com](http://www.prothena.com) and follow us on Twitter @ProthenaCorp.

### **Media & Investor Contact:**

Ellen Rose, Head of Communications  
650-922-2405, [ellen.rose@prothena.com](mailto:ellen.rose@prothena.com)

 [Prothena\\_RGB\\_fullcolor.jr](#)

Source: Prothena Corporation plc